It was supposed to be a routine Stone Age settlement excavation to clear a path for a new roundabout and water pipes near ...

Viking aims to compete against market giants Eli Lilly and Novo Nordisk in the billion-dollar weight loss drug market. The ...

With a gain of more than 531% over the last 12 months, shares of Viking Therapeutics (NASDAQ: VKTX) are a hot commodity, to ...

When it comes to pre-revenue biotechs, it's often a struggle to build an investment thesis beyond "if the medicine works, the ...

Viking christened two more new river cruise ships today in Luxor, Egypt as they expand their fleet with more custom built ...

Viking Therapeutics reported clinical trial data on Sunday, which excited some investors. Despite signs that Viking's ...

Viktor the Viking will be hosting his annual mascot game at halftime of Sunday's game, which features full-grown mascots ...

Viking Therapeutics Inc. cheered analysts Monday after the biotech posted data on its oral weight-loss drug showing ...

Wall Street analysts were impressed by data showing competitive rates of weight loss for Viking’s therapy, but shares in the ...

Viking Therapeutics’ GLP-1 pill candidate for treating obesity showed promise in its latest trial results, the clinical-stage ...

Viking Therapeutics reported an 8.2% weight loss with VK2735, but a sell-off followed. Read why VKTX stock's long-term ...

Truist Financial analyst Joon Lee assigned a Buy rating to the stock today. The company’s shares closed last Friday at $72.88. Lee covers ...